Biologists in Demand

Demand for biologists in disciplines represented by member societies of the Federation of American Societies for Experimental Biology (FASEB), especially at the postdoctoral training/research associate level, shows strong indications of exceeding the supply significantly. A combination of increasing numbers of positions and decreasing output from universities appears to be at work here; growth in size and number of biotechnology companies and decline in numbers of appropriate age groups which

Written byThomas L. Trudeau
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Demand for biologists in disciplines represented by member societies of the Federation of American Societies for Experimental Biology (FASEB), especially at the postdoctoral training/research associate level, shows strong indications of exceeding the supply significantly. A combination of increasing numbers of positions and decreasing output from universities appears to be at work here; growth in size and number of biotechnology companies and decline in numbers of appropriate age groups which actually started three decades ago—when baby boom births peaked—are reported everywhere.

The basis for these statements is experience at the FASEB placement service, which operates year-round and is particularly prominent at annual meetings such as this week’s in Las Vegas. The purpose of the service is to match candidates seeking post-doctoral training or permanent positions with recruiting employers from academe, government, and industry. Most candidates possess a doctoral degree or expect to receive one soon; however, individuals with master’s or baccalaureate ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies